On October 30, Stryker fell 5.63% in After-Hours Trading, trading at $283.00/share, with turnover of $23.60 million.
The clearest catalyst in the available information is the company’s announcement that it increased its share repurchase authorization by $3 billion, released after its October 29 quarterly report.
Leading into the print, market expectations called for September-quarter adjusted EPS of $3.56, while recent analyst sentiment remained constructive, including Evercore ISI lifting its price target to $355 from $335 on October 28. Earlier in the month, Stryker also completed the ZuriMED acquisition to add the FiberLocker System to its sports medicine portfolio. Even so, the verified market move was a decline despite these developments, indicating the stock reaction was tied to the latest post-earnings update rather than broader sector trading, which was little changed among peers such as Boston Scientific, Medtronic, Abbott Laboratories, Intuitive Surgical, and Glaukos.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments